Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Depreciation & Amortization (CF) (2020 - 2025)

Bolt Biotherapeutics' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $290000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 34.09% year-over-year to $290000.0; the TTM value through Sep 2025 reached $1.5 million, down 19.76%, while the annual FY2024 figure was $1.8 million, 3.94% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $290000.0 at Bolt Biotherapeutics, down from $347000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $467000.0 in Q1 2023 and bottomed at $256000.0 in Q2 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $426000.0 (2024), against an average of $396315.8.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 169.31% in 2021 before it plummeted 34.09% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $361000.0 in 2021, then rose by 27.98% to $462000.0 in 2022, then increased by 1.08% to $467000.0 in 2023, then dropped by 8.78% to $426000.0 in 2024, then crashed by 31.92% to $290000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Depreciation & Amortization (CF) are $290000.0 (Q3 2025), $347000.0 (Q2 2025), and $399000.0 (Q1 2025).